Universal reference book for medicines
Product name: SANORIN (SANORIN)

Active substance: naphazoline

Type: Vasoconstrictive drug for topical application in ENT practice

Manufacturer: Teva Pharmaceutical Industries (Israel) manufactured by TEVA Czech Industries (Czech Republic)
Composition, form of production and packaging
?
Nasal drops 0.05% in the form of a clear, colorless liquid.
1 ml

naphazoline nitrate 500 μg

[PRING] boric acid, ethylenediamine, methyl parahydroxybenzoate, water.

10 ml - a bottle of a dropper of dark glass (1) - packs cardboard.

?
Nasal drops 0.1% in the form of a clear, colorless liquid.
1 ml

naphazoline nitrate 1 mg

[PRING] boric acid, ethylenediamine, methylpahydroxybenzoate, water.

10 ml - a bottle of a dropper of dark glass (1) - packs cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2010.

PHARMACHOLOGIC EFFECT

Alpha 2- adrenomimetic.
When topical application has a rapid, pronounced and prolonged vasoconstrictive effect on the vessels of the mucous membrane (reduces swelling, flushing, exudation). It alleviates nasal breathing in rhinitis and reduces swelling with conjunctivitis. After 5-7 days there is tolerance.
PHARMACOKINETICS

Data on the pharmacokinetics of Sanorin are not available.

INDICATIONS

- Acute rhinitis;

- sinusitis;

- Eustachyte;

- laryngitis;

- to facilitate the conduct of a rhinoscopy;

- the need to stop nasal bleeding;

- as an additional agent in the treatment of conjunctivitis of bacterial origin (for drops of nasal 0.05%).

DOSING MODE

In acute rhinitis, sinusitis, eustachitis, laryngitis, to facilitate the carrying out of a rhinoscopy for adults, children and adolescents older than 15 years - 1-3 drops of nasal drops 0.1% or 1 to 3 doses of nasal spray in each nostril 3-4 times / day ;
drops nasal 0.1% in the form of an emulsion appoint 1-3 drops in each nasal passage 2-3 times / day.
Children older than 2 years - 1-2 drops of nasal drops 0.05% in each nasal passage 2-3 times / day with an interval of not less than 4 hours.

Apply for a short time: for adults - no more than 1 week, for children - not more than 3 days.
If nasal breathing is facilitated, Sanorin can be used sooner. Repeated use of the drug is possible in a few days.
With nosebleeds, you can put a cotton swab moistened with 0.05% Sanorin solution in the nasal passage.

As an additional remedy for the treatment of conjunctivitis of bacterial origin, a drop of 0.05% drop in drops per drop 1-2 drops 3-4 times / day is injected into the conjunctival bag.

Nasal drops in the form of an emulsion must be shaken before use.
Open the vial with the drug should be used within 4 weeks.
When using the spray for the first time, it is recommended to press the metering device several times until a compact aerosol cloud appears.
Before direct use, remove the protective cap, keep the vial in the upright position, insert the end of the dosing device into the nasal passage, then quickly and sharply push the applicator.Immediately after injection, it is recommended to breathe lightly. After applying the preparation, cover the applicator with a protective cap.
SIDE EFFECT

From the side of the digestive system: nausea.

From the cardiovascular system: tachycardia, increased blood pressure.

From the side of the central nervous system: headache, irritability.

Allergic reactions: rash.

Local reactions: reactive hyperemia, swelling of the nasal mucosa;
when applied for more than 1 week - irritation, in some cases - swelling of the nasal mucosa.
CONTRAINDICATIONS

- chronic rhinitis;

- an angle-closure glaucoma;

- arterial hypertension;

- severe atherosclerosis;

- tachycardia;

- thyrotoxicosis;

- diabetes;

- simultaneous administration of MAO inhibitors and a period of up to 14 days after the end of their use;

- Children's age under 2 years (drops nasal 0.05%);

- Children under 15 years of age (nasal drops 0.1% in solution and emulsion, nasal spray);

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

Data on the safety of the drug during pregnancy and lactation (breastfeeding) are not provided.

APPLICATION FOR CHILDREN

Children over 2 years - 1-2 drops of nasal drops 0.05% in each nostril 2-3 times / day with an interval of not less than 4 hours.

With prolonged use, the severity of the vasoconstrictor effect gradually decreases (the phenomenon of tachyphylaxis), and therefore recommended after 3 days of use in children to take a break for several days.

SPECIAL INSTRUCTIONS

With prolonged use, the severity of the vasoconstrictor effect gradually decreases (the phenomenon of tachyphylaxis), which is why it is recommended after 5-7 days of use in adults and after 3 days of use in children to take a break for several days.

The drug may have a resorptive effect.

The doctor determines the need for Sanorin with other medicines individually.

OVERDOSE

Symptoms: prolonged or frequent administration of Sanorin in the nasal cavity can cause swelling of the nasal mucosa and a feeling of its congestion.
The risk of overdose (especially if swallowed) of the drug Sanorin occurs in young children and can cause CNS depression, which manifestations include drowsiness, lower body temperature, increased sweating, slowing heart rate, increasing blood pressure or lowering it, extremely rarely - coma.
Treatment: withdrawal of the drug, symptomatic therapy.

DRUG INTERACTION

Simultaneous administration with MAO inhibitors and a period of up to 14 days after the end of their use, increases the risk of development of severe arterial hypertension (release of deposited catecholamines under the action of nafazoline).
Slows the absorption of local anesthetics.
TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of reach of children, protected from light at a temperature of 10 ° to 25 ° C.
Shelf life - 4 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!